hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06335342, orgStudyIdInfo id: IEO 0726, briefTitle: Radiotherapy Treatments for Neoplasms in the Head and Neck Region, statusModule overallStatus: RECRUITING, startDateStruct date: 2018-02-22, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: European Institute of Oncology, class: OTHER, descriptionModule briefSummary: The aim of this study is the evaluation of clinical and dosimetric aspects, tolerance, and effectiveness of radiotherapy treatments in the head and neck region.Eligible patients undergoing radiotherapy for primary or secondary neoplasms localized in the head and neck anatomical region., conditionsModule conditions: Head and Neck Neoplasms, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 4050, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Overall Survival, primaryOutcomes measure: Disease free survival, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: European Institute of Oncology, status: RECRUITING, city: Milan, country: Italy, contacts name: Barbara Alicja Jereczek, role: CONTACT, geoPoint lat: 45.46427, lon: 9.18951, hasResults: False
protocolSection identificationModule nctId: NCT06335316, orgStudyIdInfo id: wallenburg sym, briefTitle: Effect of Stellate Nerve Block in Dysphagia, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-01-01, primaryCompletionDateStruct date: 2023-05-04, completionDateStruct date: 2023-05-28, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: Copka Sonpashan, class: OTHER_GOV, descriptionModule briefSummary: This is a randomized controlled study, including dysphagic patients with bulbar palsy after ischemic stroke who were received in the department of rehabilitation medicine in China. Both groups were provided with comprehensive rehabilitation including routine rehabilitation and swallowing function training. Besides, the observation group additionally underwent the stellate ganglion block (SGB). At admission and after 20-day treatment,Yale Pharyngeal Residue Severity Rating Scale, video fluoroscopic swallowing study (VFSS), Functional Oral Intake Scale, and penetration-aspiration scale (PAS) were used to assess swallowing function., conditionsModule conditions: Dysphagia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 122, type: ACTUAL, armsInterventionsModule interventions name: Injection, interventions name: Lidocaine Hydrochloride, interventions name: Comprehensive therapy, interventions name: placebo, outcomesModule primaryOutcomes measure: Functional Oral Intake Scale, secondaryOutcomes measure: Yale Pharyngeal Residue Severity Rating Scale, secondaryOutcomes measure: penetration-aspiration scale, secondaryOutcomes measure: The Swallowing Quality of Life Questionnaire, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Huimin Hos., city: Pengfu, country: Taiwan, geoPoint lat: 24.98333, lon: 121.41667, hasResults: False
protocolSection identificationModule nctId: NCT06335303, orgStudyIdInfo id: 1462-0004, secondaryIdInfos id: 2023-508395-11-00, type: OTHER, domain: CTIS, secondaryIdInfos id: U1111-1302-4283, type: OTHER, domain: WHO, briefTitle: A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF), statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-20, primaryCompletionDateStruct date: 2026-04-30, completionDateStruct date: 2026-06-30, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: Boehringer Ingelheim, class: INDUSTRY, descriptionModule briefSummary: This study is open to adults 40 years or older with idiopathic pulmonary fibrosis (IPF). People can join the study if they are not on any treatment for IPF are on stable treatment for at least 3 months before starting the study. The purpose of this study is to find out whether a medicine called BI 1819479 helps people with IPF. 3 different doses of BI 1819479 are tested in this study.Participants are put into 4 groups by chance. Participants in 3 groups get different doses of BI 1819479. Participants in 1 group get placebo. Placebo tablets look like BI 1819479 tablets, but do not contain any medicine. Participants take the treatment for 6 months to 1 year. Participants are in the study for up to 1 year and 2 months. During this time, they visit the study site between 10 and 12 times and get up to 11 phone calls from the site staff.At site visits doctors regularly perform breathing tests that measure how well the lungs are working. Researchers compare the results between participants who take BI 1819479 and placebo. The doctors also regularly check participants' health and take note of any unwanted effects., conditionsModule conditions: Idiopathic Pulmonary Fibrosis, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, enrollmentInfo count: 300, type: ESTIMATED, armsInterventionsModule interventions name: BI 1819479, interventions name: Placebo matching BI 1819479, outcomesModule primaryOutcomes measure: Annual rate of decline in Forced Vital Capacity (FVC) [milliLiter/year], secondaryOutcomes measure: Absolute change from baseline in FVC at Week 24 [in milliLiter], eligibilityModule sex: ALL, minimumAge: 40 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06335290, orgStudyIdInfo id: IEO 725, briefTitle: Radiotherapy Treatments for the Treatment of Thoracic District Tumors, statusModule overallStatus: RECRUITING, startDateStruct date: 2018-02-22, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: European Institute of Oncology, class: OTHER, descriptionModule briefSummary: Evaluation of clinical and dosimetric aspects, tolerance, and effectiveness of thoracic radiotherapy treatments in patients undergoing radiotherapy for primary or secondary neoplasms localized in the thoracic anatomical region., conditionsModule conditions: Thoracic Neoplasms, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 13200, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Overall survival, primaryOutcomes measure: Disease free survival, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: European Institute of Oncology, status: RECRUITING, city: Milan, country: Italy, contacts name: Barbara Alicja Jereczek, role: CONTACT, geoPoint lat: 45.46427, lon: 9.18951, hasResults: False
protocolSection identificationModule nctId: NCT06335277, orgStudyIdInfo id: IEO 0727, briefTitle: Total Body Irradiation Treatments for Patients Treated at European Institute of Oncology, statusModule overallStatus: RECRUITING, startDateStruct date: 2018-02-22, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: European Institute of Oncology, class: OTHER, descriptionModule briefSummary: Patients eligible undergoing total body irradiation as candidates for bone marrow or peripheral stem cell transplant., conditionsModule conditions: Leukemia, conditions: Leukemia, Chronic, conditions: Leukemia, Acute, conditions: Lymphoma, conditions: Aplastic Anemia, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Overall Survival, primaryOutcomes measure: Disease free survival, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: European Institute of Oncology, status: RECRUITING, city: Milan, country: Italy, contacts name: Barbara Alicja Jereczek, role: CONTACT, geoPoint lat: 45.46427, lon: 9.18951, hasResults: False
protocolSection identificationModule nctId: NCT06335264, orgStudyIdInfo id: 2024-9987, briefTitle: Screening for Heart Failure Using a Multimodal Wearable Device, acronym: WEAR-HF, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-15, primaryCompletionDateStruct date: 2024-07, completionDateStruct date: 2024-12, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: McGill University Health Centre/Research Institute of the McGill University Health Centre, class: OTHER, collaborators name: HOP-Child Technologies Inc, descriptionModule briefSummary: The purpose of this study is to find out if there are any patterns in the way people's bodies react to physical activities and their voices when they have heart failure, a disease where the heart cannot function sufficiently. To do this, the investigators will use a smartwatch that can measure multiple signals like the participant's heart rate and movement. Investigators will ask participants with and without heart failure to wear the Watch HOP (from HOP-Child Technologies Inc.) and sensors during physical tasks at their clinic visit at the McGill University Health Centre. Researchers will also record the participants' voices between their visits. The key signals can help find who is at risk for heart failure or develop new ways to monitor and treat it., conditionsModule conditions: Heart Failure, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 54, type: ESTIMATED, armsInterventionsModule interventions name: Watch HOP, outcomesModule primaryOutcomes measure: Presence or absence of heart failure, secondaryOutcomes measure: left ventricular ejection fraction (LVEF), secondaryOutcomes measure: Natriuretic peptide (NT-proBNP) level, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: McGill University Health Centre, status: RECRUITING, city: Montreal, state: Quebec, zip: H4A 3J1, country: Canada, contacts name: Abhinav Sharma, MD, role: CONTACT, phone: 514 934-1934, email: dreamcvlab@muhc.mcgill.ca, contacts name: Abhinav Sharma, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 45.50884, lon: -73.58781, hasResults: False
protocolSection identificationModule nctId: NCT06335251, orgStudyIdInfo id: IEO 0728, briefTitle: Radiotherapy Treatments for Neoplasms of the Limbs, statusModule overallStatus: RECRUITING, startDateStruct date: 2018-02-22, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: European Institute of Oncology, class: OTHER, descriptionModule briefSummary: In this observational study patients treated at European Institute of Oncology with radiotherapy to limbs will be included, conditionsModule conditions: Bone Neoplasms, conditions: Bone Metastases, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 3000, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Overall survival, primaryOutcomes measure: Disease free survival, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: European Institute of Oncology, status: RECRUITING, city: Milan, country: Italy, contacts name: Barbara Alicja Jereczek, role: CONTACT, geoPoint lat: 45.46427, lon: 9.18951, hasResults: False
protocolSection identificationModule nctId: NCT06335238, orgStudyIdInfo id: IEO 0729, briefTitle: Radiotherapy Treatments for Neoplasms in the Abdominal-pelvic Region, statusModule overallStatus: RECRUITING, startDateStruct date: 2018-02-22, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: European Institute of Oncology, class: OTHER, descriptionModule briefSummary: Evaluation of clinical and dosimetric aspects, tolerance, and effectiveness of abdominal-pelvic region radiotherapy treatments in patients undergoing radiotherapy for primary or secondary neoplasms localized in the tabdominal-pelvic region., conditionsModule conditions: Abdominal Cancer, conditions: Pelvic Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 7700, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Overall survival, primaryOutcomes measure: Disease free survival, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: European Institute of Oncology, status: RECRUITING, city: Milan, country: Italy, contacts name: Barbara Alicja Jereczek, role: CONTACT, geoPoint lat: 45.46427, lon: 9.18951, hasResults: False
protocolSection identificationModule nctId: NCT06335225, orgStudyIdInfo id: 2023-NHLHCRF-YXHZ-ZRMS-06, briefTitle: Establishment of Precise Nutrition Management Scheme for Patients With Prediabetes Based on Nutrigenomics, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-13, primaryCompletionDateStruct date: 2025-07-31, completionDateStruct date: 2025-07-31, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: China-Japan Friendship Hospital, class: OTHER, descriptionModule briefSummary: With the aging of population and the change of lifestyle, the prevalence of prediabetes is increasing year by year. Nutritional factors are one of the important environmental factors in the occurrence and development of abnormal glucose metabolism. The medical nutritional treatment of diabetes is recommended as the cornerstone of diabetes treatment by various guidelines. With the development of nutrigenomics, it has been found that genes related to the absorption, metabolism, distribution and excretion of various nutrients are related to diabetes. This study intends to conduct precision nutrition intervention for prediabetic patients based on nutritional genes, and evaluate the effectiveness and safety of these nutritional interventions., conditionsModule conditions: Prediabetes, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Precise nutritional intervention, interventions name: Conventional nutritional intervention, outcomesModule primaryOutcomes measure: HbA1c, secondaryOutcomes measure: Concentration of fasting plasma glucose, secondaryOutcomes measure: Concentration of 2-hour plasma glucose, secondaryOutcomes measure: Concentration of fasting insulin, secondaryOutcomes measure: Concentration of fasting C peptide, secondaryOutcomes measure: Concentration of TC, TG, LDL-C, and HDL-C, secondaryOutcomes measure: Concentration of ALT, AST, TBIL, secondaryOutcomes measure: Concentration of creatinine, secondaryOutcomes measure: BMI, secondaryOutcomes measure: Waist hip ratio, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: China-Japan Friendship Hospital, status: RECRUITING, city: Beijing, country: China, contacts name: Xiao Ma, MD, role: CONTACT, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06335212, orgStudyIdInfo id: IRBNET ID 1448963, briefTitle: Peripheral Defocus Profile of Multifocal Minus Contact Lenses, statusModule overallStatus: COMPLETED, startDateStruct date: 2019-06-01, primaryCompletionDateStruct date: 2019-08-01, completionDateStruct date: 2019-08-05, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: State University of New York College of Optometry, class: OTHER, descriptionModule briefSummary: Purpose: Numerous studies have proven that emmetropization in young animals including humans is regulated by visual input. It has long been hypothesized that peripheral myopic defocus may act as a stop signal to reduce myopia progression and axial elongation. As such, multifocal soft contact lenses (MFCLs) have been utilized for myopia control in school-aged children, with variable efficacies. One potential explanation is that the actual peripheral myopic defocus an eye experiences during MFCL wear may not be identical to the Add power and not sufficient to reduce myopia progression. Our study investigated and compared the peripheral power profiles of myopic eyes when they were uncorrected and wore single vision contact lenses (SVCLs) and MFCLs of different Add powers.Methods: Subjects with -1.00 D to -10.00 D of myopia (SE, determined with manifest refraction) were custom fit with both single vision (SV) and MFCLs (+2.00 and +4.00 D Add; provided by Specialeyes) in both eyes. These Specialeyes MFCLs had an aspheric design with a standard total optical zone of 8.0mm. Cycloplegic central autorefraction was conducted with both Grand Seiko WAM-5500 open-field auto-refractor (Grand Seiko Co Ltd) and OPD OPD-Scan III Wavefront Aberrometer (Marco) on the subjects in the following conditions: (1) no CLs, (2) SVCLs, (3) MFCLs (+2.00D Add), and (4) MFCLs (+4.00D Add). Relative peripheral power profiles were measured using the OPD under the same 4 conditions after cycloplegia. Data in the right eye was used for analysis., conditionsModule conditions: Myopia, conditions: Refractive Errors, conditions: Contact Lens, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 19, type: ACTUAL, armsInterventionsModule interventions name: Single vision and multifocal contact lenses, outcomesModule primaryOutcomes measure: refractive power, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 30 Years, stdAges: ADULT, contactsLocationsModule locations facility: State University of New York, College of Optometry, city: New York, state: New York, zip: 10036, country: United States, geoPoint lat: 40.71427, lon: -74.00597, hasResults: False
protocolSection identificationModule nctId: NCT06335199, orgStudyIdInfo id: H24109, secondaryIdInfos id: 5P2CHD086844-09, type: NIH, link: https://reporter.nih.gov/quickSearch/5P2CHD086844-09, briefTitle: tVNS Responsiveness Testing With Pupil Size, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2025-03-31, completionDateStruct date: 2025-04-30, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: Georgia Institute of Technology, class: OTHER, collaborators name: Emory University, collaborators name: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), descriptionModule briefSummary: The goal of this study is to learn about the acute pupil response to transcutaneous vagus nerve stimulation (tVNS) in stroke survivors and healthy adults. The main question it aims to answer is whether pupil size response is greater with bilateral tVNS compared to unilateral tVNS. Participants will receive tVNS and sham at the outer ear unilaterally and bilaterally in resting condition. The pupil size of the participants will be recorded during tVNS., conditionsModule conditions: Stroke, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: SINGLE_GROUP, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 16, type: ESTIMATED, armsInterventionsModule interventions name: Unilateral tVNS stimulation, interventions name: Bilateral tVNS stimulation, interventions name: Unilateral Sham stimulation, interventions name: Bilateral Sham stimulation, outcomesModule primaryOutcomes measure: Pupil size change, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: Human Neuromuscular Physiology Lab, city: Atlanta, state: Georgia, zip: 30318, country: United States, contacts name: Minoru Shinohara, Ph.D., role: CONTACT, phone: 404-894-1030, email: shinohara@gatech.edu, geoPoint lat: 33.749, lon: -84.38798, hasResults: False
protocolSection identificationModule nctId: NCT06335160, orgStudyIdInfo id: Mebendazole Ulcerative Colitis, briefTitle: Possible Efficacy and Safety of Mebendazole in Patients With Ulcerative Colitis Treated With Mesalamine, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2025-04, completionDateStruct date: 2025-05, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: Tanta University, class: OTHER, descriptionModule briefSummary: To evaluate the possible efficacy and safety of mebendazole in patients with ulcerative colitis treated with mesalamine, conditionsModule conditions: Ulcerative Colitis, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 46, type: ESTIMATED, armsInterventionsModule interventions name: Mebendazole, outcomesModule primaryOutcomes measure: change in disease activity, primaryOutcomes measure: change in Partial Mayo Scoring Index (PMSI) assessment for Ulcerative Colitis Activity, secondaryOutcomes measure: Change in Hemoglobin Concentration, secondaryOutcomes measure: Change in Erythrocyte sedimentation rate (ESR), secondaryOutcomes measure: Change in Serum albumin, secondaryOutcomes measure: Change in Serum Interleukin -6 (IL-6), secondaryOutcomes measure: Change in Serum Nitric oxide (NO), secondaryOutcomes measure: Change in Serum Intra cellular adhesion molecule 1 (ICAM-1), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False